Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:IOVA NASDAQ:MIRM NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$38.87-4.0%$35.02$10.38▼$43.73$6.64B0.343.18 million shs2.05 million shsIOVAIovance Biotherapeutics$4.23-3.2%$3.98$1.70▼$5.63$1.89B0.712.84 million shs9.92 million shsMIRMMirum Pharmaceuticals$122.13-4.4%$106.49$50.25▼$130.00$7.45B0.481.06 million shs539,122 shsPTCTPTC Therapeutics$84.85-5.2%$75.56$43.17▼$90.87$7.04B0.532.66 million shs1.07 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-4.05%+0.47%+23.87%+6.87%+273.75%IOVAIovance Biotherapeutics-3.20%-1.86%+11.90%+14.32%+112.56%MIRMMirum Pharmaceuticals-4.36%-2.75%+29.93%+28.29%+128.45%PTCTPTC Therapeutics-5.27%+1.85%+15.68%+23.53%+74.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$38.87-4.0%$35.02$10.38▼$43.73$6.64B0.343.18 million shs2.05 million shsIOVAIovance Biotherapeutics$4.23-3.2%$3.98$1.70▼$5.63$1.89B0.712.84 million shs9.92 million shsMIRMMirum Pharmaceuticals$122.13-4.4%$106.49$50.25▼$130.00$7.45B0.481.06 million shs539,122 shsPTCTPTC Therapeutics$84.85-5.2%$75.56$43.17▼$90.87$7.04B0.532.66 million shs1.07 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-4.05%+0.47%+23.87%+6.87%+273.75%IOVAIovance Biotherapeutics-3.20%-1.86%+11.90%+14.32%+112.56%MIRMMirum Pharmaceuticals-4.36%-2.75%+29.93%+28.29%+128.45%PTCTPTC Therapeutics-5.27%+1.85%+15.68%+23.53%+74.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.86Moderate Buy$43.7312.50% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.4399.26% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$143.4017.42% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$91.577.92% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, MIRM, PTCT, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$142.00 ➝ $148.007/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/2/2026IOVAIovance Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/2/2026MIRMMirum Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$115.00 ➝ $125.006/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AIOVAIovance Biotherapeutics$263.50M7.17N/AN/A$1.76 per share2.40MIRMMirum Pharmaceuticals$521.31M14.29$0.05 per share2,395.69$6.12 per share19.96PTCTPTC Therapeutics$1.73B4.07$8.77 per share9.67($2.56) per share-33.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A531.00N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A40.213.90-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest IOVA, MIRM, PTCT, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026IOVAIovance Biotherapeutics-$0.17N/AN/AN/A$87.67 millionN/A8/6/2026Q2 2026PTCTPTC Therapeutics$0.3173N/AN/AN/A$294.00 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A7/30/2026Q2 2026MIRMMirum Pharmaceuticals-$0.7279N/AN/AN/A$166.03 millionN/A5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14IOVAIovance BiotherapeuticsN/A3.603.15MIRMMirum Pharmaceuticals1.282.091.99PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AIOVAIovance Biotherapeutics77.03%MIRMMirum PharmaceuticalsN/APTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences6.59%IOVAIovance Biotherapeutics7.80%MIRMMirum Pharmaceuticals8.32%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableIOVA, MIRM, PTCT, and COGT HeadlinesRecent News About These CompaniesReasons Why Investors Should Consider Betting on PTC Stock NowJuly 10 at 3:16 PM | zacks.comNeil Gregory Almstead Sells 22,161 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 10 at 4:29 AM | americanbankingnews.comStocks Look Shaky, But This Sector is Booming (Biotech)July 9 at 2:06 PM | zacks.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Strong-Buy" at Zacks ResearchJuly 9 at 7:35 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 5,079 SharesJuly 9 at 6:37 AM | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) VP Sells $432,121.32 in StockJuly 8 at 7:06 PM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells 22,161 SharesJuly 8 at 7:06 PM | marketbeat.comNeil Gregory Almstead Sells 24,613 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 8 at 7:06 PM | marketbeat.comPTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should KnowJuly 8 at 1:01 PM | zacks.comPTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High - Should You Buy?July 7, 2026 | marketbeat.comCPRX's Agamree Shows Potential Beyond DMD After Positive Phase I DataJuly 2, 2026 | zacks.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 2, 2026 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 2, 2026 | marketbeat.comNeil Gregory Almstead Sells 8,130 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 1, 2026 | insidertrades.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $693,163.80 in StockJune 30, 2026 | marketbeat.comPictet Asset Management Holding SA Has $80.06 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 30, 2026 | marketbeat.comLouisiana State Employees Retirement System Takes Position in PTC Therapeutics, Inc. $PTCTJune 30, 2026 | marketbeat.comOP Asset Management Ltd Acquires Shares of 33,602 PTC Therapeutics, Inc. $PTCTJune 28, 2026 | marketbeat.comNeil Gregory Almstead Sells 5,323 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 27, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 SharesJune 26, 2026 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells 20,960 Shares of StockJune 26, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, MIRM, PTCT, and COGT Company DescriptionsCogent Biosciences NASDAQ:COGT$38.87 -1.64 (-4.05%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$38.90 +0.03 (+0.07%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$4.23 -0.14 (-3.20%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$4.26 +0.03 (+0.71%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Mirum Pharmaceuticals NASDAQ:MIRM$122.13 -5.57 (-4.36%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$122.10 -0.02 (-0.02%) As of 07/10/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.PTC Therapeutics NASDAQ:PTCT$84.85 -4.70 (-5.25%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$84.85 0.00 (0.00%) As of 07/10/2026 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
